Continuing in its efforts to find a new judge for the thousands of Accutane cases pending in New Jersey state court, Hoffman-La Roche filed notice to appeal a decision by presiding Judge Carol E. Higbee not to recuse herself in the case.
The state judge overseeing Accutane mass tort litigation in New Jersey has denied Hoffmann- La Roche’s motion asking that she recuse herself.
Drug maker Hoffmann- La Roche has asked for the recusal of the New Jersey judge overseeing the Accutane mass tort litigation, asserting that Judge Carol E. Higbee is siding unfairly with plaintiffs who allege injuries from the acne drug.
Pharmaceutical company Hoffmann-La Roche adequately warned a user of the acne drug Accutane of the risk of developing inflammatory bowel disease, a U.S. District Court in Florida has ruled in granting summary judgment.
Denying a defense motion for remittitur or new trial, a New Jersey judge has affirmed a jury’s $25.16 million award to an Alabama man who suffered from inflammatory bowel disease as a result of taking the acne medication Accutane.
A trial judge improperly limited the defense’s evidence regarding the overall number of Accutane users, the New Jersey Appellate Division has ruled in reversing a $10.5 million verdict for the plaintiff.